SCD and hepatocellular carcinoma: In the light of the signaling network discussed herein, the exciting possibility of synergism between statins, SCD inhibitors, mTORC1 inhibitors (including rapamycin and its analogs), and kinase inhibitors in dampening HCC cell proliferation and migration and preventing drug resistance through inhibition of YAP/TAZ is a novel therapeutic approach that has not been examined in HCC.